Skip to main content
. 2023 Mar 1;18(3):e0282177. doi: 10.1371/journal.pone.0282177

Fig 4. C19orf57 expression and cisplatin response in PDXs.

Fig 4

(A) Therapeutic response of PDXs to cisplatin, arranged in order of increasing C19orf57 expression. (PDXs 36 and 30 are HPV+; PDXs 13, 15, 12, and 18 are HPV-). (B) C19orf57 expression, in units of log2(counts/million), for each of the six PDXs tested for cisplatin response.